Chimeric Therapeutics Ltd

Research Chimeric Therapeutics Ltd (CHM) on Bullrun: market cap AUD 3.51M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCHM
• ExchangeAU
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyAUD
• Market capAUD 3.51M
• Financial periodFY2025
• RevenueAUD 3.97M
• Net income-AUD 10.43M
• Free cash flow-AUD 7.28M
• Gross margin78.7%

Valuation Snapshot

latest market cap is AUD 3.51M.

About Chimeric Therapeutics Ltd

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors.

Frequently asked questions

What is Chimeric Therapeutics Ltd's market cap?

Chimeric Therapeutics Ltd's market capitalization is AUD 3.51M.

What does Chimeric Therapeutics Ltd do?

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia.